$79.970
+0.040 (+0.05%)Zum Schluss
Umsatzquellen von NARI
Inari Medical Inc (NARI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is VTE, accounting for 94.8% of total sales, equivalent to $145.35M. Another important revenue stream is Emerging Therapies. Understanding this composition is critical for investors evaluating how NARI navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitabilität und Margen von NARI
Evaluating the bottom line, Inari Medical Inc maintains a gross margin of 85.43%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.34%, while the net margin is -11.97%. These profitability ratios, combined with a Return on Equity (ROE) of -17.72%, provide a clear picture of how effectively NARI converts its operational activities into shareholder value.
NARI im Vergleich zur Peergroup
In the context of the broader market, NARI competes directly with industry leaders such as ITGR and SANM. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, NARI's gross margin of 85.43% stands against ITGR's 24.71% and SANM's 10.44%. Such benchmarking helps identify whether Inari Medical Inc is trading at a premium or discount relative to its financial performance.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.